The Boutique Investment Bank That Always Puts You First

We are a full-service, boutique investment bank providing corporate finance, M&A advisory, equity research, institutional sales, and market making and trading services.

The Boutique Investment Bank That Always Puts You First

We are a full-service investment bank providing corporate finance, M&A advisory, equity research, market making and institutional sales and trading services.

$ 0 B+

We Have Led Or Participated In Over $2 Billion in Transactions

Funding public companies is what we do.

We’ve invested our own capital over the years, and have relationships with institutional and strategic investors seeking quality opportunities.

Our Purpose

Your Goals Are Our Goals

Whether you’re seeking additional capital, looking to grow through acquisition, or considering the sale of your company, we can add value from our experience managing businesses and the expertise we’ve gained advising hundreds of clients.

Featured Clients

ClientLogos 300x150 02
ClientLogos 300x150 01
ClientLogos 300x150 03
ClientLogos 300x150 08
ClientLogos 300x150 08
Outlook Therapeutics
ClientLogos 300x150 08
Ascendiant Client Logos 11
Ascendiant Client Logos 12
Nemaura
Pro Dex
Endra Life Science
ClientLogos 300x150 01

Our Latest Financing Transactions

ClientLogos 300x150 01
NYSE American: NILE NYSE American: NILE NYSE American: NILE
NYSE American: NILE NYSE American: NILE NYSE American: NILE

$46,400,000

At-The-Market Offering

Sole Sales Agent

June

2022

ClientLogos 300x150 09
Nasdaq: NMRD Nasdaq: NMRD Nasdaq: NMRD
Nasdaq: NMRD Nasdaq: NMRD Nasdaq: NMRD

$6,015,000

Private Placement

Sole Placement Agent

May

2022

Ascendiant Client Logos 10
Nasdaq: PAVM Nasdaq: PAVM Nasdaq: PAVM
Nasdaq: PAVM Nasdaq: PAVM Nasdaq: PAVM

$50,000,000

Registered Direct

Financial Advisor

April

2022

Endra Life Science
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA

$9,360,000

At-The-Market Offering

Sole Sales Agent

April

2022

ClientLogos 300x150 02
Nasdaq: INTZ Nasdaq: INTZ Nasdaq: INTZ
Nasdaq: INTZ Nasdaq: INTZ Nasdaq: INTZ

$10,700,000

Private Placement

Sole Placement Agent

March

2022

ClientLogos 300x150 01
NYSE American: NILE NYSE American: NILE NYSE American: NILE
NYSE American: NILE NYSE American: NILE NYSE American: NILE

$200,000,000

At-The-Market Offering

Sole Sales Agent

February

2022

YAYO Logo
OTC: YAYO OTC: YAYO OTC: YAYO
OTC: YAYO OTC: YAYO OTC: YAYO

$13,700,000

Private Placement

Placement Agent

January

2022

ClientLogos 300x150 08
Nasdaq: AIRT Nasdaq: AIRT Nasdaq: AIRT
Nasdaq: AIRT Nasdaq: AIRT Nasdaq: AIRT

$12,000,000

At-The-Market Offering

Sole Sales Agent

November

2021

Outlook Therapeutics
Nasdaq: OTLK Nasdaq: OTLK Nasdaq: OTLK
Nasdaq: OTLK Nasdaq: OTLK Nasdaq: OTLK

$10,220,000

Private Placement

Financial Advisor

November

2021

ClientLogos 300x150 08
Nasdaq: NXTP Nasdaq: NXTP Nasdaq: NXTP
Nasdaq: NXTP Nasdaq: NXTP Nasdaq: NXTP

$1,665,000

Private Placement

Sole Placement Agent

October

2021

ClientLogos 300x150 03
Nasdaq: LUCD Nasdaq: LUCD Nasdaq: LUCD
Nasdaq: LUCD Nasdaq: LUCD Nasdaq: LUCD

$70,000,000

Initial Public Offering

Financial Advisor

October

2021

Endra Life Science
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA

$20,000,000

At-the-Market Offering

Sole Sales Agent

June

2021

AIRTINC
Nasdaq: AIRT Nasdaq: AIRT Nasdaq: AIRT
Nasdaq: AIRT Nasdaq: AIRT Nasdaq: AIRT

$8,000,000

At-the-Market Offering

Sole Sales Agent

May

2021

MOnaker Group
Nasdaq: MKGI Nasdaq: MKGI Nasdaq: MKGI
Nasdaq: MKGI Nasdaq: MKGI Nasdaq: MKGI

$9,370,000

Private Placement

Sole Placement Agent

March

2021

Ault Global Holdings
NYSE American: DPW NYSE American: DPW NYSE American: DPW
NYSE American: DPW NYSE American: DPW NYSE American: DPW

$200,000,000

At-the-Market Offering

Sole Sales Agent

March

2021

Endra Life Science
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA
Nasdaq: NDRA Nasdaq: NDRA Nasdaq: NDRA

$12,600,000

At-the-Market Offering

Sole Sales Agent

February

2021

Ault Global Holdings
NYSE American: DPW NYSE American: DPW NYSE American: DPW
NYSE American: DPW NYSE American: DPW NYSE American: DPW

$125,000,000

At-the-Market Offering

Sole Sales Agent

February

2021

Our Latest M&A Transactions

Ascendiant Client Logos 12

acquired Technology Assessment & Transfer

Sole M&A Advisor

July
2022
Pinnacleprecisionsheetmedal Logo

has been acquired by The Partner Companies

Sole M&A Advisor

June
2022
South East

has been acquired by Pac-Dent, Inc.

Sole M&A Advisor

November
2021
ClientLogos 300x150 08

has been acquired by Vista Apex Dental

Sole M&A Advisor

October
2021
Ascendiant Client Logos 10

has acquired CapNostics, LLC

Sole M&A Advisor

October
2021
Ascendiant Client Logos 11

has been acquired by Gladstone Inv Corp

Sole M&A Advisor

August
2021
Gold Tech Industries

has been acquired by Graycliff Partners LP

Sole M&A Advisor

July
2021
Ascendiant Client Logos 12

acquired the assets of B4C, LLC

Sole M&A Advisor

July
2021
Vista Dental

has been acquired by Inverness Graham

Sole M&A Advisor

June
2018
Triex Tower

has been acquired by CED

Sole M&A Advisor

April
2018
Safe Flo (1)

has been acquired by Crosstex International

Sole M&A Advisor

December
2017
Riverside

has been acquired by Champlain Financial

Sole M&A Advisor

July
2017
Bulls Eye

has been acquired by GSM Outdoors

Sole M&A Advisor

July
2017
Who We Are

What makes us the "go-to" investment bank

We’ve started, managed, and sold businesses of our own. Most investors and bankers have only worked on transactions, they’ve never run a business. Let us share our knowledge and insights to help you and your company

Our Values

01/08

Relationships

We’re in the money business, but we’re really in the people business. Investing in long-term relationships with clients is a fundamental principle of our business strategy, and one of the most rewarding and enjoyable aspects of what we do.

Our Values

02/08

Trust

Trust, along with excellent communication, is essential in any relationship. We value honesty, integrity, transparency, and reliability, and pledge to always do our best to earn your trust.

Our Values

03/08

Highest Standards

We’re not here to sell you, we’re here to serve you. That means doing what is best for your company and your shareholders – based on your needs and objectives, not ours. We’ve run businesses, too, and now we run an investment bank – that will always put you first.

Our Values

04/08

Serve Clients

Our goal is not to be the biggest bank, it’s to be the best – for the clients we serve. Your best financial partner, your best advisor, your best strategist, your best resource, your best sounding board. The best an investment bank has to offer.

Our Values

05/08

Success

Here’s our simple business philosophy and formula for success – maximize relationships, not fees. Success for us is a client achieving its goals and realizing its potential. When our capital is structured in a way that truly meets your needs – and allows you to hire more employees, open a new building, expand R&D, sell more product, or secure a strategic acquisition, that’s our measure of success.

Our Values

06/08

Experience

Most investors and bankers you meet have never run a business, and even fewer have managed a public company. We have unique perspective and insight from your side of the desk because we’ve been there. We appreciate what you do – tackling challenges and pursuing opportunities – and want to do our best to support you. Let our experience and expertise help you make the best decisions for your company.

Our Values

07/08

Freedom

A public company needs support from a lot of sources to achieve success. That means multiple investors, analysts, shareholders, and yes, investment banks. In short, you need a lot of investment bank friends, not just one. When an investment bank requires exclusivity or a right of first refusal following a capital raise, they are leveraging the relationship and limiting your company’s options. When you work with us, you have freedom, and that’s best for your business.

Our Values

08/08

Respect

Some investment banks are run like a money printing machine – deal after deal, and fees on top of fees. You get calls, e-mails, and texts all hours of the day, night, and weekends, pushing you to accept an offer. That’s not our style, and we’re respectful of your time and your life away from the office. We’ll listen to your needs and objectives, present ideas and solutions, and let you make the call.

Client Testimonial

“Ascendiant is very client-focused, and they are particularly astute at understanding the obstacles and pressures a micro-cap public company and management team faces. Our corporate structure is complex and somewhat unusual, and Ascendiant’s research analysts are adept at providing an in-depth investor report and analysis. We’re very appreciative of our relationship with Ascendiant, and the support they provide.”
Ascendiant Michael Feldschuh

Michael Feldschuh

CEO & President

Daxor Corporation (Nasdaq: DXR)

Ascendiant By The Numbers

$ 0 B+
In Financing Transactions
0 +
M&A Transactions
0 +
Covered Companies
0 +
Years In Business

What We Do

Value-Added Services Backed by Experience and Dedication

With Ascendiant, you’re not another name on a spreadsheet.  You’re a client we care about now and well into the future. We’ll listen to your needs and objectives, and do our best to apply our skills, experience, and expertise to your situation.

Pexels Kampus Production 8353777

Corporate Finance

We provide equity capital, debt financing, and related strategic guidance and advisory services to public and private companies, while generating investment opportunities for institutional, accredited, and strategic investors.  Ascendiant’s Investment Banking division also assists private companies interested in going public.

Pexels Sora Shimazaki 5668834

Mergers & Acquisitions

Ascendiant Capital Markets, LLC provides advisory services for Mergers & Acquisitions in both a sell-side and buy-side capacity. The members of Ascendiant’s Investment Banking division average over twenty-five years of experience, and have successfully initiated, negotiated, and completed over 300 M&A transactions across a wide range of industry sectors.    

Equity Research

Ascendiant’s Equity Research team provides independent research, analysis, and reporting to the investment community for sectors such as: healthcare (biotech, life sciences, medical device), technology, energy, consumer, media and entertainment, and the internet.

Institutional Sales

Ascendiant’s Institutional Sales division supports the efforts of Ascendiant’s Equity Research division, generating investment ideas and high-value market research for the firm’s institutional clients and investment managers.

Market Making & Trading

Ascendiant’s Market Making & Trading division utilizes the firm’s capital to provide liquidity, while making markets in a significant number of equity securities.  Our traders average over fifteen years’ experience, and provide reliable and efficient order execution.

Access Our Research Reports

NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM
NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM

AIM Q4 2021

Ascendiant Research Report

NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM
NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM NYSE American: AIM

AIM Q1 2022

Ascendiant Research Report

Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN
Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN Nasdaq: ALZN

ALZN Q3 FY22

Ascendiant Research Report

Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX
Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX

AMTX Q4 2021

Ascendiant Research Report

Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX
Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX Nasdaq: AMTX

AMTX Q1 2022

Ascendiant Research Report

Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS
Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS

ATOS Q4 2021

Ascendiant Research Report

Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS
Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS Nasdaq: ATOS

ATOS Q1 2022

Ascendiant Research Report

Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI
Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI

ATVI Q4 2021

Ascendiant Research Report

Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI
Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI Nasdaq: ATVI

ATVI Q1 2022

Ascendiant Research Report

Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO
Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO

AUTO Q1 2022

Ascendiant Research Report

Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO
Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO Nasdaq: AUTO

AUTO Q4 2021

Ascendiant Research Report

Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL
Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL

BIOL Q4 2021

Ascendiant Research Report

Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL
Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL Nasdaq: BIOL

BIOL Q1 2022

Ascendiant Research Report

Ascendiant News

July 6, 2022
Ascendiant Serves as Sole M&A Advisor on SINTX Technologies, Inc.’s (Nasdaq: SINT) Acquisition of Technology Assessment & Transfer, Inc. (TA&T)
June 27, 2022
Ascendiant Initiates Research Coverage on Blackboxstocks Inc. (Nasdaq: BLBX)
June 23, 2022
Ascendiant Capital Markets LLC serves as Sole M&A Advisor on Sale of Pinnacle Precision to The Partner Companies
June 15, 2022
Ascendiant Capital Markets LLC serves as Sole Sales Agent on $46,400,000 At-the-Market (ATM) Offering for BitNile Holdings, Inc.’s Series D Preferred Stock (NYSE American: NILE PRD)
May 31, 2022
Ascendiant Serves as Sole Placement Agent on $6,015,000 Private Placement for Nemaura Medical, Inc. (Nasdaq: NMRD), Increases Total Amount to $36,045,000 over Three Transactions
April 7, 2022
Ascendiant Serves as Financial Advisor on $50,000,000 Registered Direct for PAVmed Inc. (Nasdaq: PAVM)
April 4, 2022
Ascendiant Serves as Sole Sales Agent on $9,360,000 At-The-Market (ATM) Offering for ENDRA Life Sciences, Inc. (Nasdaq: NDRA)
March 10, 2022
Ascendiant Serves as Sole Placement Agent on $10,700,000 Private Placement for Intrusion, Inc. (Nasdaq: INTZ)
February 28, 2022
Ascendiant Serves as Sole Sales Agent on $200,000,000 At-the-Market (ATM) Offering for BitNile Holdings, Inc. (NYSE American: NILE)
January 24, 2022
Ascendiant Initiates Research Coverage on SurgePays, Inc. (Nasdaq: SURG)
January 11, 2022
Ascendiant Serves as Placement Agent on $13,700,000 Public Offering for EVmo, Inc.
December 26, 2021
Ascendiant Initiates Research Coverage on Lucid Diagnostics, Inc. (Nasdaq: LUCD)